Clinical study “PREV-HAP” submitted for approval

The Clinical Trial Application for the PREV-HAP study: “Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international, phase 2, randomized, placebo-controlled trial – the PREV-HAP study“, has been submitted by CHU-Nantes for approval to the regulatory authorities (France, Spain and Greece).

Next steps:

We expect an approval or a list of queries on the submitted documents by 30.11.2020, and aim to complete the VHP procedure by the end of the year.